0TDD Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 100.10 |
| 52 Week High | DKK 149.80 |
| 52 Week Low | DKK 94.77 |
| Beta | 0.16 |
| 11 Month Change | -15.07% |
| 3 Month Change | -25.98% |
| 1 Year Change | -2.93% |
| 33 Year Change | 78.84% |
| 5 Year Change | 248.23% |
| Change since IPO | 244.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0TDD | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -8.4% | -1.0% | -0.4% |
| 1Y | -2.9% | -4.0% | 5.6% |
Return vs Industry: 0TDD exceeded the UK Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: 0TDD underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| 0TDD volatility | |
|---|---|
| 0TDD Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0TDD has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0TDD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 71,880 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| 0TDD fundamental statistics | |
|---|---|
| Market cap | US$444.65b |
| Earnings (TTM) | US$13.37b |
| Revenue (TTM) | US$38.19b |
33.0x
P/E Ratio11.6x
P/S RatioIs 0TDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0TDD income statement (TTM) | |
|---|---|
| Revenue | DKK 270.58b |
| Cost of Revenue | DKK 41.51b |
| Gross Profit | DKK 229.07b |
| Other Expenses | DKK 134.35b |
| Earnings | DKK 94.72b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 21.38 |
| Gross Margin | 84.66% |
| Net Profit Margin | 35.01% |
| Debt/Equity Ratio | 47.3% |
How did 0TDD perform over the long term?
See historical performance and comparison